Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | April 2008 |
| End Date: | September 2011 |
Cohort Study of the Relationship of Hyperlipidemia and Statin Therapy on Survival and Disease Progresssion in Amyotrophic Lateral Sclerosis
The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis
(ALS) pathophysiology and its impact on disease progression and survival is unclear. The
investigators analyzed the correlation between lipid levels with disease progression and
survival in ALS patients and the association of LLT with these outcomes.
(ALS) pathophysiology and its impact on disease progression and survival is unclear. The
investigators analyzed the correlation between lipid levels with disease progression and
survival in ALS patients and the association of LLT with these outcomes.
Inclusion Criteria:
- A clinical diagnosis of laboratory-supported probable, probable, or definite familial,
sporadic ALS, according to a modified El Escorial criteria (ref), by the study
investigators
- Time from disease onset is less than three years
- 18 years of age
- Subjects with diagnosis of hyperlipidemia and/or taking lipid lowering medications
will not be excluded from study.
Exclusion Criteria:
- Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per
day
- Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,
etc)
- A clinically significant history of significant medical illness (advanced cancer,
chronic inflammatory/infectious conditions, etc) within six months of baseline
- Use of progestins, anabolic steroids, and corticosteroids within 45 days of baseline
visit. Therapy is allowed as medically indicated after baseline visit.
We found this trial at
1
site
Click here to add this to my saved trials
